Skip to main content

Association Between High Deductible Health Plans and Cost-Related Non-adherence to Medications Among Americans with Diabetes: an Observational Study

Abstract

Background

For people with diabetes, adherence to prescribed medications is essential. However, the rising prevalence of high-deductible health plans (HDHPs), and prices of diabetes medications such as insulin, could deter adherence.

Objective

To assess the impact of HDHP on cost-related medication non-adherence (CRN) among non-elderly adults with diabetes in the US.

Design

Repeated cross-sectional survey.

Setting

National Health Interview Survey, 2011–2018.

Participants

A total of 7469 privately insured adults ages 18–64 with diabetes who were prescribed medications and enrolled in a HDHP or a traditional commercial health plan (TCP).

Main Measures

Self-reported measures of CRN were compared between enrollees in HDHPs and TCPs overall and among the subset using insulin. Analyses were adjusted for demographic and clinical characteristics using multivariable linear regression models.

Key Results

HDHP enrollees were more likely than TCP enrollees to not fill a prescription (13.4% vs 9.9%; adjusted percentage point difference (AD) 3.4 [95% CI 1.5 to 5.4]); skip medication doses (11.4% vs 8.5%; AD 2.8 [CI 1.0 to 4.7]); take less medication (11.1% vs 8.8%; AD 2.3 [CI 0.5 to 4.0]); delay filling a prescription to save money (14.4% vs 10.8%; AD 3.0 [CI 1.1 to 4.9]); and to have any form of CRN (20.4% vs 15.5%; AD 4.4 [CI 2.2 to 6.7]). Among those taking insulin, HDHP enrollees were more likely to have any CRN (25.1% vs 18.9%; AD 5.9 [CI 1.1 to 10.8]).

Conclusion

HDHPs are associated with greater CRN among people with diabetes, particularly those prescribed insulin. For people with diabetes, enrollment in non-HDHPs might reduce CRN to prescribed medications.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800-5.

    Article  Google Scholar 

  2. 2.

    Egede LE, Gebregziabher M, Echols C, Lynch CP. Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother. 2014;48(5):562-70.

    Article  Google Scholar 

  3. 3.

    Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175-94.

    Article  Google Scholar 

  4. 4.

    Aikens JE, Piette JD. Longitudinal association between medication adherence and glycaemic control in type 2 diabetes. Diabet Med. 2013;30(3):338-44.

    CAS  Article  Google Scholar 

  5. 5.

    Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-41.

    Article  Google Scholar 

  6. 6.

    Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.

    Article  Google Scholar 

  7. 7.

    Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149-53.

    CAS  Article  Google Scholar 

  8. 8.

    American Diabetes A. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36 Suppl 1:S11-66.

    Article  Google Scholar 

  9. 9.

    Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-9.

    CAS  Article  Google Scholar 

  10. 10.

    Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22(6):864-71.

    Article  Google Scholar 

  11. 11.

    Kesselheim AS, Huybrechts KF, Choudhry NK, Fulchino LA, Isaman DL, Kowal MK, et al. Prescription drug insurance coverage and patient health outcomes: a systematic review. Am J Public Health. 2015;105(2):e17-30.

    Article  Google Scholar 

  12. 12.

    Zhang JX, Meltzer DO. The high cost-related medication non-adherence rate among medicare-medicaid dual-eligible diabetes patients. J Health Med Econ. 2016;2(2).

  13. 13.

    Karter AJ, Parker MM, Solomon MD, Lyles CR, Adams AS, Moffet HH, et al. Effect of out-of-pocket cost on medication initiation, adherence, and persistence among patients with type 2 diabetes: the Diabetes Study of Northern California (DISTANCE). Health Serv Res. 2018;53(2):1227-47.

    Article  Google Scholar 

  14. 14.

    Herkert D, Vijayakumar P, Luo J, Schwartz JI, Rabin TL, DeFilippo E, et al. Cost-related insulin underuse among patients with diabetes. JAMA Intern Med. 2018.

  15. 15.

    Kang H, Lobo JM, Kim S, Sohn MW. Cost-related medication non-adherence among U.S. adults with diabetes. Diabetes Res Clin Pract. 2018;143:24-33.

    Article  Google Scholar 

  16. 16.

    Rabin DL, Jetty A, Petterson S, Saqr Z, Froehlich A. Among low-income respondents with diabetes, high-deductible versus no-deductible insurance sharply reduces medical service use. Diabetes Care. 2017;40(2):239-45.

    Article  Google Scholar 

  17. 17.

    Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25(6):1015-21.

    Article  Google Scholar 

  18. 18.

    Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. JAMA. 2016;315(13):1400-2.

    Article  Google Scholar 

  19. 19.

    Tribble SJ. Flurry of federal and state probes target insulin drugmakers and pharma middlemen. https://khn.org/news/flurry-of-federal-and-state-probes-target-insulin-drugmakers-and-pharma-middlemen/. Accessed June 25, 2020.

  20. 20.

    Luo J, Avorn J, Kesselheim AS. Trends in Medicaid reimbursements for insulin from 1991 through 2014. JAMA Intern Med. 2015;175(10):1681-6.

    Article  Google Scholar 

  21. 21.

    Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. JAMA. 2014;311(22):2331-3.

    CAS  Article  Google Scholar 

  22. 22.

    Claxton G, Rae M, Long M, Damico A, Whitmore H. The Kaiser Family Foundation Employer Health Benefits 2018 Annual Survey. October 3, 2018. Accessed at: https://www.kff.org/report-section/2018-employer-health-benefits-survey-section-1-cost-of-health-insurance/.

  23. 23.

    Wharam JF, Zhang F, Eggleston EM, Lu CY, Soumerai S, Ross-Degnan D. Diabetes outpatient care and acute complications before and after high-deductible insurance enrollment: a Natural Experiment for Translation in Diabetes (NEXT-D) Study. JAMA Intern Med. 2017;177(3):358-68.

    Article  Google Scholar 

  24. 24.

    Abdus S, Keenan PS. Financial burden of employer-sponsored high-deductible health plans for low-income adults with chronic health conditions. JAMA Intern Med. 2018;178(12):1706-8.

    Article  Google Scholar 

  25. 25.

    Segel JE, Kullgren JT. Health insurance deductibles and their associations with out-of-pocket spending and affordability barriers among US adults with chronic conditions. JAMA Intern Med. 2017;177(3):433-6.

    Article  Google Scholar 

  26. 26.

    Chua KP, Lee JM, Conti RM. Out-of-pocket spending for insulin, diabetes-related supplies, and other health care services among privately insured US patients with type 1 diabetes. JAMA Intern Med. 2020.

  27. 27.

    Wharam JF, Lu CY, Zhang F, Callahan M, Xu X, Wallace J, et al. High-deductible insurance and delay in care for the macrovascular complications of diabetes. Ann Intern Med. 2018;169(12):845-54.

    Article  Google Scholar 

  28. 28.

    Gaffney A, White A, Hawks L, Himmelstein D, Woolhandler S, Christiani DC, et al. High-deductible health plans and healthcare access, use, and financial strain in those with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2020;17(1):49-56.

    Article  Google Scholar 

  29. 29.

    Lewey J, Gagne JJ, Franklin J, Lauffenburger JC, Brill G, Choudhry NK. Impact of high deductible health plans on cardiovascular medication adherence and health disparities. Circ Cardiovasc Qual Outcomes. 2018;11(11):e004632.

    Article  Google Scholar 

  30. 30.

    Center for Disease Control and Prevention. National Center for Health Statistics National Health Interview Survey. About the National Health Interview Survey. Accessed at: https://www.cdc.gov/nchs/nhis/about_nhis.htm.

  31. 31.

    Piette JD, Wagner TH, Potter MB, Schillinger D. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care. 2004;42(2):102-9.

    Article  Google Scholar 

  32. 32.

    Ross-Degnan D, Wallace J, Zhang F, Soumerai SB, Garabedian L, Wharam JF. Reduced cost-sharing for preventive drugs preferentially benefits low-income patients with diabetes in high deductible health plans with health savings accounts. Med Care. 2020;58 Suppl 6 Suppl 1:S4-S13.

    Article  Google Scholar 

  33. 33.

    Rogers MAM, Lee JM, Tipirneni R, Banerjee T, Kim C. Interruptions In private health insurance and outcomes in adults with type 1 diabetes: a longitudinal study. Health Aff (Millwood). 2018;37(7):1024-32.

    Article  Google Scholar 

  34. 34.

    Reiss SK, Ross-Degnan D, Zhang F, Soumerai SB, Zaslavsky AM, Wharam JF. Effect of switching to a high-deductible health plan on use of chronic medications. Health Serv Res. 2011;46(5):1382-401.

    Article  Google Scholar 

  35. 35.

    Nair K, Park J, Wolfe P, Saseen J, Read Allen R, Ganguly R.. Consumer- driven health plans: impact on utilization and expenditures for chronic disease sufferers. J Occup Environ Med. 2009;51: 594–602.

    Article  Google Scholar 

  36. 36.

    Li R, Barker LE, Shrestha S, Zhang P, Duru OK, Pearson-Clarke T, et al. Changes over time in high out-of-pocket health care burden in U.S. adults with diabetes, 2001-2011. Diabetes Care. 2014;37(6):1629-35.

    Article  Google Scholar 

  37. 37.

    Meiri A, Zhang F, Ross-Degnan D, Wharam JF. Trends in insulin out-of-pocket costs and reimbursement price among us patients with private health insurance, 2006-2017. JAMA Intern Med. 2020.

  38. 38.

    Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858-71.

    Article  Google Scholar 

  39. 39.

    Internal Revenue Service IRS expands list of preventive care for HSA participants to include certain care for chronic conditions. Published July 17, 2019. https://www.irs.gov/newsroom/irs-expands-list-of-preventive-care-for-hsa-participants-to-include-certain-care-for-chronic-conditions. Accessed January 7, 2020.

Download references

Author information

Affiliations

Authors

Contributions

There were no contributors that did not meet authorship criteria.

Corresponding author

Correspondence to Vikas Gampa MD.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 43.5 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rastas, C., Bunker, D., Gampa, V. et al. Association Between High Deductible Health Plans and Cost-Related Non-adherence to Medications Among Americans with Diabetes: an Observational Study. J GEN INTERN MED (2021). https://doi.org/10.1007/s11606-021-06937-9

Download citation

KEY WORDS

  • insurance
  • cost
  • diabetes